波士顿科学 BSX 深 沪
等待开盘 06-26 09:30:00 美东时间
44.195
-0.265
-0.60%
华盛通- 最 高45.83
- 今 开44.21
- 成交量 1452.59万股
- 最 低 43.89
- 昨 收 44.46
- 总市值 6315.47万
- 52周最高 109.4994
- 市盈率 静 64.33
- 换手率 1016.51%
- 52周最低 43.89
- 委 比 5.56%
- 总股本 0.01亿
- 历史最高 109.4994
- 量 比 0.80
- 振 幅 4.36%
- 历史最低 4.79
- 每 手 1
- 风险率 19.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wolfe Research Downgrades Boston Scientific to Peer Perform
Wolfe Research analyst Mike Polark downgrades Boston Scientific (NYSE:BSX) from Outperform to Peer Perform.
05-29 20:22
Boston Scientific Advances Coronary Calcium Treatment With Positive Trial Results
Boston Scientific reported positive FRACTURE trial results for its SEISMIQ 4CE coronary IVL catheter in severe CAD patients.
05-20 00:01
Boston Scientific Announces $2B Accelerated Share Buyback Program
Boston Scientific Corporation (NYSE:BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association for $2 billion (the repurchase price) of
05-18 19:14
被夜尿问题困扰多年！新疆老人远赴成都选择瑞梦消融术！【四川瑞梦前列腺治疗医院】
“晚上终于能睡个安稳觉了！”在四川结石病医院泌尿外科病房里，84岁的陈先生脸上洋溢着久违的轻松。就在不久前，这位从新疆远道而来的老人，还因前列腺增生导致的尿频...
04-28 12:12
5 Early Q1 Earnings Winners Beating Expectations
Earnings season is here and some big stocks like Tesla, AmEx, and Intel have already reported strong results. 5 companies with potential for more gains: GEV, ISRG, JNJ, PYPL, and UNH.
04-25 00:28
Boston Scientific Drops Despite Encouraging Trial Readouts
Boston Scientific shares fall after WATCHMAN FLX and EKOS trial updates, as analysts adjust ratings and price targets despite positive data.
03-31 00:44
8 Stocks to Buy as Merger-Mania Takes Over
Consolidation wave creates opportunities for patient investors. 8 sectors leading now are health, semiconductors, medical devices, and media.
03-11 00:42
Boston Scientific Halts Use Of Select Stent Delivery Devices After Patient Deaths
Boston Scientific removes certain AXIOS stents after deployment issues linked to 167 injuries and three deaths, FDA says.
02-27 03:28
Boston Scientific Analyst Slashes Price Target On Disappointing 2026 Outlook
Boston Scientific beats Q4 estimates but gives disappointing 2026 guidance, with slowing organic growth and lowered price target.
02-06 00:11
Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface
FDA is reviewing AXIOS stent delivery issues after Boston Scientific reported injuries and deaths, urging facilities to stop use and remove affected devices.
01-22 01:30
